Search

Displaying results 2091 - 2100 of 10000 in total
  1. Drug

    Picosulfuric acid

    go.drugbank.com/drugs/DB09268
    ApprovedInvestigational

    Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery.

    Mixtures: CITRAFLEET 0.01 G/ 3.50 G/ 10.97 G ORAL ÇÖZELTI HAZIRLAMAK IÇIN TOZ IÇEREN SAŞE , 2 ADET, PICOPREP 10 MG / 3,5 G /12 G ORAL ÇÖZELTI IÇIN TOZ, 2 SAŞECategories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Anacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (_Ananas comosus_ [L.] Merr.). … It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  3. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. … [L42425] Pegloticase has a longer terminal elimination half-life thanks to the addition of a polyethylene glycol (PEG) group.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.

    Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideCategories: MATE 1 Inhibitors, P-glycoprotein inhibitors
  5. Drug

    Relebactam

    go.drugbank.com/drugs/DB12377
    ApprovedInvestigational

    Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam]. … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568]

    Categories: MATE 1 Substrates, MATE 2 Substrates
  6. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … , resulting in a premature termination of the trial.

    Categories: Heterocyclic Compounds, 2-RingProducts: DORVAK®, DORIPURE® 500
  7. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. … [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: MEKINIST®2 MG TABLETAS RECUBIERTAS, MEKINIST 2 MG FILM KAPLI TABLET ,7 TABLET
  8. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … exercising caution in their recommendation as much more research is necessary [A32981, A32982].

    Synonyms: (S)-pyroglutamic acid, (S)-(−)-2-pyrrolidone-5-carboxylic acidMixtures: 2% Salicylic Acid FACIAL CLEANSER
  9. Drug

    Mentha arvensis leaf oil

    go.drugbank.com/drugs/DB16575
    Investigational

    Mixtures: TIGER BALM PLASTER-RD, TIGER MEDICATED PLASTER - RD
  10. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. … [A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates